<DOC>
	<DOCNO>NCT00376584</DOCNO>
	<brief_summary>This 12-week clinical trial lipid clinic patient niacin therapy appropriate evaluate efficacy MK0524 improve tolerability extended-release niacin . There 6 schedule clinic visit 3 treatment arm .</brief_summary>
	<brief_title>Effect Investigational Compound Tolerability Extended Release Niacin ( 0524A-023 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient appropriate candidate niacin therapy Patients evidence ischemic cardiovascular disease must statin LDLC &lt; 130 mg/dL V1 Patients diabetes mellitus evidence ischemic cardiovascular disease must LDLC &lt; 130 mg/dL V1 Nondiabetic patient 2 risk factor coronary heart disease ischemic cardiovascular disease must LDLC &lt; 160 mg/dL V1 Patient TG &lt; 500 mg/dL ( 5.65 mmol/L ) V1 A patient historic serum plasma lipid value measure within 6 month Visit 1 may use meet lipid inclusion criterion ALL OTHER PATIENTS DO NOT REQUIRE SPECIFIC LIPID ENTRY CRITERIA Patients unstable dos medication Pregnant lactate woman , woman intend become pregnant exclude Patients diabetes mellitus poorly control , unstable newly diagnose Patients : chronic heart failure , uncontrolled/unstable cardiac arrhythmia , unstable hypertension , active chronic hepatobiliary disorder hepatic disease , HIV positive , gout ( within 1 year )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Hypercholesteremia</keyword>
	<keyword>Mixed Hyperlipidemia</keyword>
</DOC>